RenovoRx, Inc. (RNXT) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon. I will be your conference call operator today. Please note that today's call is being recorded, and all participants, other than management, are in listen-only mode. There will be a Q&A session following management's presentation. I will now turn the call over to Valter Pinto, Managing Director of KCSA Strategic Communications. Please go ahead. Thank you, operator. Good afternoon and welcome everyone to the RenovoRx second quarter of 2026 financial results conference call. I'm joined today by members of our leadership team, including Shaun Bagai, chief executive officer, Dr. Ramtin Agah, chief medical officer, executive chair and founder, and Mark Voll, chief financial officer. Before we begin, I'd like to remind everyone that statements made during today's call contain or may contain forward-looking statements covered by the Safe Harbor Provisions of the Private Security Litigation Reform Act of 1995 and applicable federal securities laws. These statements, including statements regarding RenovoRx's clinical and commercial plans, strategies, and estimates, or expectations of financial or operational performance, including revenue, are based on management's current plans and assumptions, and actual results may differ materially. Please refer to our filings with the SEC, including our Form 10-Q for the quarter ended June 30th, 2026, for a detailed discussion of the risks and uncertainties facing Renovo Rx. With that, I now turn the call over to our Chief Executive Officer, Shaun Bagai. Thank you, Walter, and good afternoon, everyone. Over the past several quarters, we set out three milestones for Renovo Rx. In this quarter, we delivered on all three. First, revenue growth. The second quarter was a record revenue quarter, our strongest to date. Second, c...